Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170.

TitleInterruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170.
Publication TypeJournal Article
Year of Publication2007
AuthorsSkiest DJ, Su Z, Havlir DV, Robertson KR, Coombs RW, Cain P, Peterson T, Krambrink A, Jahed N, McMahon D, Margolis DM
Corporate AuthorsAIDS Clinical Trials Group 5170 Study Team
JournalJ Infect Dis
Volume195
Issue10
Pagination1426-36
Date Published2007 May 15
ISSN0022-1899
KeywordsAcquired Immunodeficiency Syndrome, Adult, Anti-HIV Agents, Anti-Retroviral Agents, CD4 Lymphocyte Count, Disease Progression, Female, Humans, Male, Middle Aged, Monitoring, Physiologic, Patient Selection, Prospective Studies, Survival Analysis, Viral Load
Abstract

BACKGROUND: We sought to determine the safety of treatment interruption (TI) and to identify parameters that would define patients with human immunodeficiency virus (HIV) for whom TI is safer.

METHODS: AIDS Clinical Trials Group 5170 was a multicenter, 96-week-long, prospective study of HIV-infected patients receiving antiretroviral therapy (ART) who had CD4(+) cell counts >350 cells/mm(3) and who underwent TI.

RESULTS: A total of 167 patients were enrolled. The median nadir in CD4(+) cell count was 436 cells/mm(3). The initial decrease (i.e., during the first 8 weeks) in CD4(+) cell count after ART interruption was 20 cells/mm(3)/week; the subsequent decrease was 2.0 cells/mm(3)/week until week 96. Both the CD4(+) cell count before enrollment and the increase in CD4(+) cell count during ART predicted early decrease; later decrease was predicted by the level of interleukin-7 at enrollment. A Centers for Disease Control and Prevention (CDC) diagnosis of a category B or C event was made for 2 and 2 patients, respectively (all had CD4(+) cell counts >350 cells/mm(3)). At week 96, 17 patients had CD4(+) cell counts < or =250 cells/mm(3), and 46 patients had resumed ART; 5 patients died (unrelated to HIV or acquired immunodeficiency syndrome). In a multivariate analysis, a higher nadir in CD4(+) cell count (>400 cells/mm(3)), a lower HIV load (<50 copies/mL) at the time of TI, and an HIV load < or =22,000 copies/mL before ART predicted a longer time to the primary end point (CDC category B or C event, death, CD4(+) cell count < or =250 cells/mm(3), or resumption of ART).

CONCLUSION: Disease progression after TI was low in this cohort. A higher nadir in CD4(+) cell count, a lower HIV load before ART, and an HIV load < or =50 copies/mL at the time of TI predicted a longer time to the primary end point.

DOI10.1086/512681
Alternate JournalJ. Infect. Dis.
PubMed ID17436222
Grant List3 U01 AI046375-05 / AI / NIAID NIH HHS / United States
5-M01RR00044 / RR / NCRR NIH HHS / United States
5-P30-AI-045008-07 / AI / NIAID NIH HHS / United States
5U01 AI027666 / AI / NIAID NIH HHS / United States
5U01-AI-39156-09 / AI / NIAID NIH HHS / United States
5U01AI032782 / AI / NIAID NIH HHS / United States
AI 27664 / AI / NIAID NIH HHS / United States
AI-25897 / AI / NIAID NIH HHS / United States
AI25859 / AI / NIAID NIH HHS / United States
AI25868 / AI / NIAID NIH HHS / United States
AI25903 / AI / NIAID NIH HHS / United States
AI25915 / AI / NIAID NIH HHS / United States
AI27658 / AI / NIAID NIH HHS / United States
AI27660 / AI / NIAID NIH HHS / United States
AI27661 / AI / NIAID NIH HHS / United States
AI27665 / AI / NIAID NIH HHS / United States
AI27670 / AI / NIAID NIH HHS / United States
AI27673 / AI / NIAID NIH HHS / United States
AI38855 / AI / NIAID NIH HHS / United States
AI38858 / AI / NIAID NIH HHS / United States
AI46370 / AI / NIAID NIH HHS / United States
AI46381 / AI / NIAID NIH HHS / United States
AI46386 / AI / NIAID NIH HHS / United States
AI50410 / AI / NIAID NIH HHS / United States
M01 RR00096 / RR / NCRR NIH HHS / United States
M01RR00047 / RR / NCRR NIH HHS / United States
RR00046 / RR / NCRR NIH HHS / United States
U01-AI 032783-13 / AI / NIAID NIH HHS / United States